Mepolizumab super-responders
According to our definition, 19%, (11/58) of MEPO subjects who completed trials were super-responders, which constituted 25.6%, (11/43) of MEPO responders. At baseline, MEPO super-responders (supplementary Table E5) had significantly lower ACQ6 [Mean(SD), super-responder: 1.93(1.33) vs non-super-responder: 3.03(1.24), P=0.016], higher AQLQ [Mean(SD), super-responder: 5.16(1.40) vs non-super-responder: 4.09(1.13), P=0.018], more exacerbations [Median(IQR), super-responder: 7(5) vs non-super-responder: 4(5), P=0.010] and better Clinic FEV1% [Mean(SD), super-responder: 79.73(19.97) vs non-super-responder: 63.07(19.84), P=0.016]. Additionally, super-responders also had a significantly lower BMI [Median (IQR), super-responder: 25.1(5) vs non-super-responder: 29.9(12.3), P=0.009] and a lower prevalence of obesity (BMI≥30 kgm-2) [super-responders: 9.1%,(1/11) vs non-super-responder: 48.9%,(23/47), P= 0.019]. Multivariate analysis (Table 2) found that more exacerbations and better ACQ6 at baseline were independently associated with MEPO super-response.